Featured Research

from universities, journals, and other organizations

Score system to predict likelihood of diabetes remission after weight-loss surgery

Date:
September 16, 2013
Source:
Geisinger Health System
Summary:
Researchers have developed a simple scoring system, based on four readily available preoperative patient characteristics, that can predict which candidates for gastric bypass surgery are likely to achieve type 2 diabetes remission within 5 years. A predictive model is likely to help patients and clinicians better manage the disease and could even save lives.

Geisinger researchers have developed a simple scoring system (DiaRem), based on four readily available preoperative patient characteristics, that can predict which candidates for gastric bypass surgery are likely to achieve Type 2 diabetes remission within 5 years. A predictive model is likely to help patients and clinicians better manage the disease and could even save lives.

"Our novel DiaRem score will give patients and physicians a scientifically valid way of assessing the merits of gastric bypass surgery for treating diabetes and deciding whether additional measures should be taken to improve the odds of remission," explains lead author George Argyropoulos, PhD from Geisinger's Sigfried and Janet Weis Center for Research Friday in The Lancet Diabetes & Endocrinology.

Roux-en-Y gastric bypass (RYGB) is used to help people who are morbidly obese lose weight. As a side effect, it has been shown to resolve or improve type 2 diabetes in roughly 60 percent of patients. It may also be useful to treat diabetes in people who are not morbidly obese. But, currently there is no accurate method to determine which patients have the greatest likelihood of remission after surgery.

To create the scoring system, researchers from the Weis Center for Research, the Center for Health Research, the Center for Nutrition and Weight Management, and the Department of Surgery combed through Geisinger's advanced Electronic Health Record to retrospectively analyze the outcomes of 690 obese patients with type 2 diabetes who underwent RYGB between 2004 and 2011 at Geisinger. Of these patients, 463 (63%) achieved partial or complete type 2 remission of type 2 diabetes.

The researchers found that obesity surgery success in reducing/reversing type 2 diabetes could be effectively predicted based on four standard clinical measures -- insulin use, age, haemoglobin A1c concentration (HbA1c; a measure of blood sugar), and type of anti-diabetic drugs. DiaRem scores were derived by assigning a certain number of points to each of the four factors.

"The DiaRem score will help guide patients and their clinicians in their selection of appropriate treatment and management of type 2 diabetes," noted Christopher D. Still, DO, director of Geisinger's Obesity Institute.

More than 20 million Americans have Type 2 diabetes; most are overweight or obese. Diabetics face increased risks for heart disease and strokes, and poorly controlled diabetes can damage the eyes, kidneys and blood vessels.

Nationwide, about 160,000 people undergo various types of obesity surgery each year. RYGB surgery, the type studied, involves stapling the stomach to create a small pouch and attaching it to the lower intestine.

Aside from the personal health toll, there's also a financial cost. For instance, obesity surgery costs about $40,000 in Pennsylvania, depending on the negotiated rate with the person's health plan. (These costs are not what the patient pays, but the average costs for the provider.)

The researchers believe that further prospective studies will help identify additional uses for the scoring process.


Story Source:

The above story is based on materials provided by Geisinger Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. Christopher D Still, G Craig Wood, Peter Benotti, Anthony T Petrick, Jon Gabrielsen, William E Strodel, Anna Ibele, Jamie Seiler, Brian A Irving, Melisa P Celaya, Robin Blackstone, Glenn S Gerhard, George Argyropoulos. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. The Lancet Diabetes & Endocrinology, 2013; DOI: 10.1016/S2213-8587(13)70070-6

Cite This Page:

Geisinger Health System. "Score system to predict likelihood of diabetes remission after weight-loss surgery." ScienceDaily. ScienceDaily, 16 September 2013. <www.sciencedaily.com/releases/2013/09/130916103356.htm>.
Geisinger Health System. (2013, September 16). Score system to predict likelihood of diabetes remission after weight-loss surgery. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/09/130916103356.htm
Geisinger Health System. "Score system to predict likelihood of diabetes remission after weight-loss surgery." ScienceDaily. www.sciencedaily.com/releases/2013/09/130916103356.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins